Detailed Narrative
Oncology Portfolio Strength and Pipeline
Johnson & Johnson is on track to become the #1 oncology company by 2030 with over $50 billion in sales, driven by 22.3% operational sales growth in Q2. Key progress includes multiple myeloma treatments like DARZALEX, CARVYKTI (sales of $439M, >100% growth), TECVAYLI, and TALVEY, with new 5-year data for CARVYKTI showing long-term remission and 100% ORR for an investigational trispecific antibody. In lung cancer, RYBREVANT plus LAZCLUZE delivered $179M in sales with >100% growth, showing strong launch uptake and intent to prescribe. The company also received FDA priority review for TAR-200 in bladder cancer, anticipating a launch later this year with expected peak sales of at least $5 billion.
Immunology Innovation and Growth
The Immunology portfolio continues to expand treatment options, with TREMFYA growing 30% in the quarter, driven by strong uptake in Crohn's disease and ulcerative colitis. TREMFYA is expected to generate at least $10 billion annually in peak year sales. The company plans to file icotrokinra, a targeted oral peptide for plaque psoriasis, with the FDA in Q3, which has shown similar efficacy to biologics and has potential in ulcerative colitis. This highlights a strategy of moving beyond traditional biologics to oral therapies and co-antibody approaches.
Neuroscience Expansion and Market Leadership
J&J aims to be the #1 Neuroscience company by the end of the decade. SPRAVATO grew 53% in Q2, demonstrating strong demand for difficult-to-treat depression. The acquisition of Intra-Cellular Therapies added CAPLYTA, approved for schizophrenia and bipolar depression, with an anticipated major depressive disorder approval later this year. CAPLYTA is expected to achieve over $5 billion in peak year sales, solidifying growth above analyst expectations.
MedTech Cardiovascular Momentum
Cardiovascular delivered over 22% operational sales growth in Q2, making J&J a leader in this fast-growing MedTech segment. This was driven by new product performance in Abiomed (16.9% growth) and Shockwave, as well as strength in electrophysiology (9.8% growth). The company has completed over 10,000 VARIPULSE cases globally with a low neurovascular event rate and is advancing solutions like the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter and OMNYPULSE. Shockwave's IVL technology is expected to be a $13 billion MedTech platform by year-end.
Surgery and Vision Portfolio Performance
Surgery grew 1.8%, supported by technology penetration in wound closure and Biosurgery, despite competitive pressures and China VBP. The Ethicon 4000 surgical stapler was introduced, and the OTTAVA robotic surgery system completed its first clinical cases, with an FDA de novo submission planned for next year. Vision saw 4.6% growth, with surgical vision up 8.9%, driven by ACUVUE OASYS MAX 1-Day contact lenses and TECNIS Odyssey/PureSee IOLs. The launch of the first disposable multifocal lenses for astigmatism is expected to further boost growth.
Financial Outlook and Strategic Investments
The company raised its full-year sales guidance by $2 billion and EPS guidance by $0.25, reflecting strong Q2 performance and favorable FX. The full-year operating margin improvement of approximately 300 basis points was reiterated. The anticipated tariff impact🌐 for 2025 was reduced from $400 million to $200 million, with the differential reinvested into pipeline acceleration. J&J reaffirmed its commitment to invest $55 billion in the U.S. over the next four years, supported by recent tax policies, aiming to manufacture all U.S.-consumed medicines domestically.